RESUMO
BACKGROUND: Neurocognitive impairment remains a common complication of human immunodeficiency virus (HIV) despite effective antiretroviral therapy (ART). We previously reported improved neurocognitive functioning with ART initiation in 7 resource-limited countries for HIV+ participants from the AIDS Clinical Trials Group (ACTG) 5199 International Neurological Study (INS). Here, we apply normative data from the International Neurocognitive Normative Study (INNS) to INS to provide previously unknown rates of neurocognitive impairment. METHODS: The A5199 INS assessed neurocognitive and neurological performance within a randomized clinical trial with 3 arms containing World Health Organization first-line recommended ART regimens (ACTG 5175; PEARLS). The ACTG 5271 INNS collected normative comparison data on 2400 high-risk HIV-negative participants from 10 voluntary counseling and testing sites aligned with INS. Normative comparison data were used to create impairment ratings for HIV+ participants in INS; associations were estimated using generalized estimating equations. RESULTS: Among 860 HIV+ adults enrolled in ACTG 5199, 55% had no neurocognitive impairment at baseline. Mild neurocognitive impairment was found in 25%, moderate in 17%, and severe in 3% of participants. With the initiation of ART, the estimated odds of impairment were reduced 12% (95% confidence interval, 9%, 14%) for every 24 weeks (P < .0001) on ART. Mild impairment dropped slightly and then remained at about 18% out to week 168. CONCLUSIONS: Almost half of HIV+ participants had neurocognitive impairment at baseline before ART, based on local norms. With ART initiation, there were significant overall reductions in neurocognitive impairment over time, especially in those with moderate and severe impairments. CLINICAL TRIALS REGISTRATION: NCT00096824.
Assuntos
Infecções por HIV/complicações , Recursos em Saúde , Transtornos Neurocognitivos/epidemiologia , Transtornos Neurocognitivos/virologia , Adulto , Fármacos Anti-HIV/uso terapêutico , Terapia Antirretroviral de Alta Atividade , Feminino , Infecções por HIV/tratamento farmacológico , Infecções por HIV/epidemiologia , Humanos , Internacionalidade , Estudos Longitudinais , Masculino , Transtornos Neurocognitivos/classificação , Testes Neuropsicológicos , Prevalência , Estudos Prospectivos , Carga ViralRESUMO
BACKGROUND: AIDS Clinical Trial Group 5199 compared neurological and neuropsychological test performance of human immunodeficiency virus type 1 (HIV-1)-infected participants in resource-limited settings treated with 3 World Health Organization-recommended antiretroviral (ART) regimens. We investigated the impact of tuberculosis (TB) on neurological and neuropsychological outcomes. METHODS: Standardized neurological and neuropsychological examinations were administered every 24 weeks. Generalized estimating equation models assessed the association between TB and neurological/neuropsychological performance. RESULTS: Characteristics of the 860 participants at baseline were as follows: 53% female, 49% African; median age, 34 years; CD4 count, 173 cells/µL; and plasma HIV-1 RNA, 5.0 log copies/mL. At baseline, there were 36 cases of pulmonary, 9 cases of extrapulmonary, and 1 case of central nervous system (CNS) TB. Over the 192 weeks of follow-up, there were 55 observations of pulmonary TB in 52 persons, 26 observations of extrapulmonary TB in 25 persons, and 3 observations of CNS TB in 2 persons. Prevalence of TB decreased with ART initiation and follow-up. Those with TB coinfection had significantly poorer performance on grooved pegboard (P < .001) and fingertapping nondominant hand (P < .01). TB was associated with diffuse CNS disease (P < .05). Furthermore, those with TB had 9.27 times (P < .001) higher odds of reporting decreased quality of life, and had 8.02 times (P = .0005) higher odds of loss of productivity. CONCLUSIONS: TB coinfection was associated with poorer neuropsychological functioning, particularly the fine motor skills, and had a substantial impact on functional ability and quality of life. CLINICAL TRIALS REGISTRATION: NCT00096824.
Assuntos
Disfunção Cognitiva/diagnóstico , Coinfecção/complicações , Infecções por HIV/complicações , Recursos em Saúde/provisão & distribuição , Doenças do Sistema Nervoso/diagnóstico , Tuberculose/complicações , Adulto , Disfunção Cognitiva/microbiologia , Disfunção Cognitiva/virologia , Coinfecção/microbiologia , Coinfecção/virologia , Feminino , HIV-1 , Humanos , Internacionalidade , Estudos Longitudinais , Masculino , Destreza Motora , Doenças do Sistema Nervoso/microbiologia , Doenças do Sistema Nervoso/virologia , Testes Neuropsicológicos , Estudos Prospectivos , Qualidade de Vida , Tuberculose/virologiaRESUMO
Neurocognitive assessment plays a central role in the diagnosis of human immunodeficiency virus- (HIV) associated neurocognitive disorders (HAND). The history of diagnostic categories and labeling of HIV-related neurological disorders is briefly presented. The current diagnostic nomenclature of HAND and the role of neurocognitive assessment is examined. Though neurocognitive testing is sensitive in assessing a broad range of cognitive impairments, neurocognitive testing is not specific to HAND without consideration of the impact on functional status, as well as confounding factors, including premorbid status.